HIV TREATMENT
2020
Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
2022 Rome Action Plan on Paediatric HIV & TB
WHO PQ
All partners commit to:
163. Address inequities by tackling the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accessing testing and treatment.
164. Increase literacy about CD4 testing and viral load and promote a client-centred approach to support expansion of access to viral load for pregnant and breastfeeding women and children on treatment, including at the point-of-care.
165. Review and assess emerging co-infections for immunocompromised infants and children, including those with advanced HIV disease, such as severe bacterial infections, fungal infections, and others for country consideration and implementation.
166. Engage affected communities for input and guidance on investment and programmatic priorities, provide support to in-country civil society organizations to engage in advocacy and demand creation for new tools, and ensure data is publicly available to support communities and civil society to monitor progress regarding uptake and implementation of essential diagnostic tools.
-
WHO PQ commits to:
270. Continue to convene the Paediatric Regulatory network to accelerate national registration through reliance and facilitate in-country registration of specific products under the Collaborative procedure established by WHO.
WHO-PQ and US FDA commit to:
271. WHO-PQ and US FDA to collaborate and agree on the next steps for the CRPlite.
-
WHO (PQ) commits to:
461. Ensure that new paediatric formulations are prioritized for WHO PQ review.
462. Promote the use of the WHO Collaborative Registration Procedure based on PQ or SRA approval to expedite national review of paediatric TB drugs and formulations.
463. Expand CRP Light beyond the pilot sites and discuss with USFDA the choice of products.
-